CY1110468T1 - Χρηση αναστολεων γλυκοσιδασης για μια θεραπεια της κυστικης ινωσεως - Google Patents

Χρηση αναστολεων γλυκοσιδασης για μια θεραπεια της κυστικης ινωσεως

Info

Publication number
CY1110468T1
CY1110468T1 CY20091100518T CY091100518T CY1110468T1 CY 1110468 T1 CY1110468 T1 CY 1110468T1 CY 20091100518 T CY20091100518 T CY 20091100518T CY 091100518 T CY091100518 T CY 091100518T CY 1110468 T1 CY1110468 T1 CY 1110468T1
Authority
CY
Cyprus
Prior art keywords
treatment
cystic fibrosis
glucosidase
antololes
group
Prior art date
Application number
CY20091100518T
Other languages
Greek (el)
English (en)
Inventor
Frédéric Becq
Caroline Norez
Original Assignee
Centre National De La Recherche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique (Cnrs) filed Critical Centre National De La Recherche Scientifique (Cnrs)
Publication of CY1110468T1 publication Critical patent/CY1110468T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CY20091100518T 2003-11-07 2009-05-14 Χρηση αναστολεων γλυκοσιδασης για μια θεραπεια της κυστικης ινωσεως CY1110468T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0313134A FR2861991B1 (fr) 2003-11-07 2003-11-07 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
EP04805405A EP1680105B1 (fr) 2003-11-07 2004-11-05 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose

Publications (1)

Publication Number Publication Date
CY1110468T1 true CY1110468T1 (el) 2015-04-29

Family

ID=34508347

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100518T CY1110468T1 (el) 2003-11-07 2009-05-14 Χρηση αναστολεων γλυκοσιδασης για μια θεραπεια της κυστικης ινωσεως

Country Status (24)

Country Link
US (2) US7973054B2 (cg-RX-API-DMAC7.html)
EP (1) EP1680105B1 (cg-RX-API-DMAC7.html)
JP (1) JP4740868B2 (cg-RX-API-DMAC7.html)
KR (2) KR20100038452A (cg-RX-API-DMAC7.html)
CN (1) CN100534432C (cg-RX-API-DMAC7.html)
AT (1) ATE423561T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004289083B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0416228A (cg-RX-API-DMAC7.html)
CA (1) CA2545133C (cg-RX-API-DMAC7.html)
CY (1) CY1110468T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004019674D1 (cg-RX-API-DMAC7.html)
DK (1) DK1680105T3 (cg-RX-API-DMAC7.html)
ES (1) ES2321725T3 (cg-RX-API-DMAC7.html)
FR (1) FR2861991B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20090159T1 (cg-RX-API-DMAC7.html)
IL (1) IL175453A (cg-RX-API-DMAC7.html)
NO (1) NO336904B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ547261A (cg-RX-API-DMAC7.html)
PL (1) PL1680105T3 (cg-RX-API-DMAC7.html)
PT (1) PT1680105E (cg-RX-API-DMAC7.html)
RU (1) RU2358725C2 (cg-RX-API-DMAC7.html)
SI (1) SI1680105T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005046672A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603726B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
DE602007008870D1 (de) * 2006-04-24 2010-10-14 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
AU2009290848A1 (en) * 2008-09-11 2010-03-18 Galapagos Nv Method for identifying compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant Cystic Fibrosis transmembrane conductance regulator
ITFE20080032A1 (it) * 2008-10-23 2010-04-24 Azienda Ospedaliera Istituti Ospit Alieri Di Vero Effetto anti infiammatorio del miglustat cellule dell'epitelio bronchiale
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
GB201006434D0 (en) 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
CA2924026C (en) * 2013-09-16 2021-12-28 Emergent Virology Llc Deoxynojirimycin derivatives and methods of their using
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
JP6851964B2 (ja) 2014-09-30 2021-03-31 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
US20190391160A1 (en) * 2016-04-29 2019-12-26 Institut Pasteur Methods and compositions for modifying cystic fibrosis transmembrane conductance regulator activity
US10478427B2 (en) * 2016-07-07 2019-11-19 National University Corporation Chiba University Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
HRP20251697T1 (hr) * 2017-06-01 2026-02-27 Idorsia Pharmaceuticals Ltd Kristalni oblik n-butildeoksigalaktonojirimicina
CN108187051A (zh) * 2018-01-30 2018-06-22 中国药科大学 α-L-岩藻糖苷酶及抑制剂用于制备防治心肌缺血损伤的药物的用途
CN116419754A (zh) * 2020-08-26 2023-07-11 科威里克斯医疗有限公司 用于治疗和预防肺部感染的葡萄糖苷酶抑制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1998020123A2 (en) * 1996-11-04 1998-05-14 Institut Curie Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins
ID21411A (id) * 1997-12-10 1999-06-10 Takeda Chemical Industries Ltd Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU5799500A (en) * 1999-06-29 2001-01-22 Mcgill University Human alpha 1,2-mannosidase
US6476194B1 (en) * 1999-06-29 2002-11-05 National Research Council Of Canada Method for folding unfolded proteins
WO2001021769A2 (en) * 1999-09-23 2001-03-29 Mcgill University THREE-DIMENSIONAL STRUCTURE AND CRYSTAL OF A CLASS I α1,2-MANNOSIDASE, AND METHODS OF USE THEREOF
AU2002359327A1 (en) * 2001-10-30 2003-05-12 Thomas Jefferson University Method of treating viral infections
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
JP5589165B2 (ja) 2003-01-31 2014-09-17 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー タンパク質欠損性障害の治療のための併用療法
US7071341B2 (en) * 2003-02-28 2006-07-04 Council Of Scientific And Industrial Research α-Glucosidase inhibitors and their synthesis from a natural source

Also Published As

Publication number Publication date
US8242136B2 (en) 2012-08-14
AU2004289083B2 (en) 2009-12-03
US20070213357A1 (en) 2007-09-13
US20110269795A1 (en) 2011-11-03
IL175453A (en) 2012-09-24
CN1897933A (zh) 2007-01-17
BRPI0416228A (pt) 2007-01-02
ATE423561T1 (de) 2009-03-15
CA2545133C (fr) 2013-04-16
AU2004289083A1 (en) 2005-05-26
PL1680105T3 (pl) 2009-07-31
CA2545133A1 (fr) 2005-05-26
ZA200603726B (en) 2007-12-27
CN100534432C (zh) 2009-09-02
IL175453A0 (en) 2008-03-20
HRP20090159T1 (en) 2009-05-31
JP4740868B2 (ja) 2011-08-03
RU2006119914A (ru) 2007-12-20
DE602004019674D1 (de) 2009-04-09
NO336904B1 (no) 2015-11-23
US7973054B2 (en) 2011-07-05
WO2005046672A3 (fr) 2005-09-15
ES2321725T3 (es) 2009-06-10
DK1680105T3 (da) 2009-06-29
PT1680105E (pt) 2009-05-20
NZ547261A (en) 2009-11-27
WO2005046672A2 (fr) 2005-05-26
RU2358725C2 (ru) 2009-06-20
KR20060130058A (ko) 2006-12-18
NO20062617L (no) 2006-07-25
SI1680105T1 (sl) 2009-08-31
FR2861991A1 (fr) 2005-05-13
FR2861991B1 (fr) 2008-01-18
EP1680105B1 (fr) 2009-02-25
KR20100038452A (ko) 2010-04-14
JP2007510699A (ja) 2007-04-26
KR100979276B1 (ko) 2010-08-31
EP1680105A2 (fr) 2006-07-19

Similar Documents

Publication Publication Date Title
IS6309A (is) Kínasólínafleiður
CO5150227A1 (es) Compuestos de triazol y su utilizacion
CY1108025T1 (el) Παραγωγα n-[φαινυλο (πιπεριδινο-2-υλο)μεθυλο] βενζαμιδιου, η διαδικασια παρασκευης τους και η εφαρμογη τους στη θεραπευτικη
SE7607201L (sv) Forfarande for framstellning av nya tienopyridinderivat
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
YU18999A (sh) Supstituisani tricikli
ES2126068T3 (es) Derivados de estilbeno citotoxicos y composicion farmaceutica que los contiene.
CY1115533T1 (el) Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
CY1106753T1 (el) Καρβαμιδικαι ενωσεις δια χρησιν εις προληψιν ή νοσηλειαν νευροεκφυλιστικων διαταραχων
EP1490371A4 (en) TRICYCLIC COMPOUNDS BASED ON THIOPENE AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS
CY1107677T1 (el) Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine
CY1110284T1 (el) Παραγωγα της 2-αμινο-4-πυριδυλομεθυλο-θειαζολινης και η χρηση τους ως αναστολεις της επαγωγιμης συνθασης νο
DK0390654T3 (da) Aminobenzensulfonsyrederivater
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
CY1109085T1 (el) Νεα αλατα
KR950703554A (ko) 피페라진 유도체 및 그의 염(piperazine derivatives and salts thereof)
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
AR010098A1 (es) COMPOSICION Y PROCEDIMIENTO PARA LA DEFORMACION PERMANENTE DEL CABELLO, Y PROCEDIMIENTO DE PREPARACIoN DE DICHA COMPOSICION
LT2006036A (en) Vaccine composition admixed with an alkylphosphatidylcholine
DK1663122T3 (da) Mundskyllesammensætninger indeholdende N-acyl-argininalkylestersalte
ATE447949T1 (de) Vakuolar-typ (h+)-atpase-hemmende verbindungen, zusammensetzungen und deren verwendungen